Loss-of-function mutations in <i>ndh</i> do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in <i>Mycobacterium tuberculosis</i>-Reference-Cited by-同舟云学术

Loss-of-function mutations in ndh do not confer delamanid, ethionamide, isoniazid, or pretomanid resistance in Mycobacterium tuberculosis

Published:2024-01-10 Issue:1 Volume:68 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Pandey Sushil¹^ORCID,Vilchèze Catherine²^ORCID,Werngren Jim³^ORCID,Bainomugisa Arnold¹^ORCID,Mansjö Mikael³^ORCID,Groenheit Ramona³^ORCID,Miotto Paolo⁴^ORCID,Cirillo Daniela M.⁴^ORCID,Coulter Christopher¹^ORCID,Baulard Alain R.⁵^ORCID,Schön Thomas⁶⁷⁸,Jacobs William R.²^ORCID,Djaout Kamel⁵^ORCID,Köser Claudio U.⁹^ORCID

Affiliation:

1. Queensland Mycobacterium Reference Laboratory, Pathology Queensland , Brisbane, Queensland, Australia

2. Department of Microbiology and Immunology, Albert Einstein College of Medicine , Bronx, New York, USA

3. Public Health Agency of Sweden , Solna, Sweden

4. Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute , Milan, Italy

5. Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille , Lille, France

6. Department of Infectious Diseases, Linköping University Hospital , Linköping, Sweden

7. Division of Infection and Inflammation, Institute of Biomedical and Clinical Sciences, Linköping University , Linköping, Sweden

8. Department of Infectious Diseases, Region Östergötland and Kalmar County Hospital, Linköping University , Linköping, Sweden

9. Department of Genetics, University of Cambridge , Cambridge, United Kingdom

Abstract

ABSTRACT Results from clinical strains and knockouts of the H37Rv and CDC1551 laboratory strains demonstrated that ndh ( Rv1854c ) is not a resistance-conferring gene for isoniazid, ethionamide, delamanid, or pretomanid in Mycobacterium tuberculosis . This difference in the susceptibility to NAD-adduct-forming drugs compared with other mycobacteria may be driven by differences in the absolute intrabacterial NADH concentration.

Funder

National Institute of Health Grant

Programme d'Investissements d'Avenir "Mustart"

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01096-23

Reference15 articles.

1. Altered NADH/NAD + Ratio Mediates Coresistance to Isoniazid and Ethionamide in Mycobacteria

2. Adduct Formation of Delamanid with NAD in Mycobacteria

3. World Health Organization . 2022. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update. https://apps.who.int/iris/handle/10665/365308.

4. Multi-clonal evolution of multi-drug-resistant/extensively drug-resistant Mycobacterium tuberculosis in a high-prevalence setting of Papua New Guinea for over three decades

5. Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid